NCT02900469View on ClinicalTrials.gov

Presurgical Trial of Denosumab in Breast Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

December 3, 2019

Study Completion Date

January 3, 2020

Conditions
Breast Cancer
Interventions
BIOLOGICAL

denosumab

denosumab: 120 mg subcutaneous injection

PROCEDURE

Surgery

Surgery: approximately 2-4 weeks after dosing of denosumab

Trial Locations (1)

10016

NYU Perlmutter Cancer Center, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT02900469 - Presurgical Trial of Denosumab in Breast Cancer | Biotech Hunter | Biotech Hunter